Cochrane · systematic review · CD007963
Oxcarbazepine for neuropathic pain
Zhou, M, Chen, N, He, L, et al. · Cochrane Database of Systematic Reviews · 2017 · Cochrane Library
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
4
current version
GRADE rated
4
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 3 · 75%Low 0 · 0%Moderate 1 · 25%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Show all 2 versionsOxcarbazepine versus placebo for painful diabetic neuropathy
Population: people with painful diabetic neuropathy
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Reduction in participant‐reported pain scores by at least 50% from the baseline VAS Oxcarbazepine vs placebo | RR 1.91 [1.08, 3.39] | 1 study · 146 participants | Very low Downgraded: risk of bias, imprecision, inconsistency, publication bias |
Reduction in participant‐reported pain scores by at least 30% from the baseline VAS Oxcarbazepine vs placebo | RR 1.57 [1.01, 2.44] | 1 study · 146 participants | Very low Downgraded: risk of bias, imprecision, inconsistency, publication bias |
Participants' global impression of their change in pain Participant's global assessment of therapeutic effect, 'much' or 'very much' Oxcarbazepine vs placebo | RR 1.46 [1.13, 1.88] | 2 studies · 493 participants | Very low Downgraded: risk of bias, inconsistency, publication bias |
Serious adverse effects Oxcarbazepine vs placebo | RR 3.65 [1.45, 9.2] | 3 studies · 634 participants | Moderate Downgraded: imprecision |